Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W. Friedberg, Christopher A. Yasenchak, Dipti Patel‐Donnelly et al.|Blood|2023Cited by 42